SPDR S&P Biotech ETF (NYSEARCA:XBI) Shares Sold by Belpointe Asset Management LLC

Belpointe Asset Management LLC lowered its holdings in SPDR S&P Biotech ETF (NYSEARCA:XBI) by 88.9% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 4,125 shares of the exchange traded fund’s stock after selling 33,025 shares during the quarter. Belpointe Asset Management LLC’s holdings in SPDR S&P Biotech ETF were worth $296,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. JPMorgan Chase & Co. lifted its stake in shares of SPDR S&P Biotech ETF by 98.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 3,265,715 shares of the exchange traded fund’s stock valued at $313,084,000 after purchasing an additional 1,622,372 shares during the period. Duality Advisers LP purchased a new position in shares of SPDR S&P Biotech ETF in the 4th quarter valued at approximately $51,363,000. First Republic Investment Management Inc. lifted its stake in shares of SPDR S&P Biotech ETF by 1.6% in the 3rd quarter. First Republic Investment Management Inc. now owns 523,329 shares of the exchange traded fund’s stock valued at $50,171,000 after purchasing an additional 8,257 shares during the period. LPL Financial LLC lifted its stake in shares of SPDR S&P Biotech ETF by 19.9% in the 3rd quarter. LPL Financial LLC now owns 343,810 shares of the exchange traded fund’s stock valued at $32,961,000 after purchasing an additional 57,179 shares during the period. Finally, Main Management ETF Advisors LLC lifted its stake in shares of SPDR S&P Biotech ETF by 6.1% in the 4th quarter. Main Management ETF Advisors LLC now owns 266,400 shares of the exchange traded fund’s stock valued at $19,114,000 after purchasing an additional 15,300 shares during the period.

Shares of XBI traded down $1.06 on Wednesday, reaching $85.86. The stock had a trading volume of 4,498,777 shares, compared to its average volume of 4,954,082. SPDR S&P Biotech ETF has a 12-month low of $64.38 and a 12-month high of $101.55.

WARNING: “SPDR S&P Biotech ETF (NYSEARCA:XBI) Shares Sold by Belpointe Asset Management LLC” was first published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this piece of content on another site, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.baseballdailydigest.com/news/2019/04/24/spdr-sp-biotech-etf-xbi-shares-sold-by-belpointe-asset-management-llc.html.

About SPDR S&P Biotech ETF

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Recommended Story: Stock Split

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.